ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)

ClinicalTrials.gov ID: NCT02964338

Public ClinicalTrials.gov record NCT02964338. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 6:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache

Study identification

NCT ID
NCT02964338
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Enrollment
259 participants

Conditions and interventions

Interventions

  • Fremanezumab Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 16, 2017
Primary completion
Jul 17, 2018
Completion
Jul 17, 2018
Last update posted
Nov 8, 2021

2017 – 2018

United States locations

U.S. sites
32
U.S. states
18
U.S. cities
31
Facility City State ZIP Site status
Teva Investigational Site 13834 Phoenix Arizona 85018
Teva Investigational Site 13819 Canoga Park California 91303
Teva Investigational Site 13811 Santa Monica California 90404
Teva Investigational Site 13823 Stanford California 94305
Teva Investigational Site 13837 Aurora Colorado 80045
Teva Investigational Site 13814 Colorado Springs Colorado 80918
Teva Investigational Site 13836 Denver Colorado 80218
Teva Investigational Site 13813 Englewood Colorado 80113
Teva Investigational Site 13821 New Haven Connecticut 06510-2483
Teva Investigational Site 13812 Stamford Connecticut 06905
Teva Investigational Site 13810 Gainesville Florida 32607
Teva Investigational Site 13815 Orlando Florida 32806
Teva Investigational Site 13829 Ormond Beach Florida 32174
Teva Investigational Site 13830 St. Petersburg Florida 33709
Teva Investigational Site 13840 Tampa Florida 33634
Teva Investigational Site 34222 Augusta Georgia 30901
Teva Investigational Site 13833 Columbus Georgia 31904
Teva Investigational Site 13826 Chicago Illinois 60614
Teva Investigational Site 13818 Ann Arbor Michigan 48104
Teva Investigational Site 13835 Las Vegas Nevada 89106
Teva Investigational Site 13832 Las Vegas Nevada 89113
Teva Investigational Site 13831 Lebanon New Hampshire 03756
Teva Investigational Site 13820 Princeton New Jersey 08540
Teva Investigational Site 13827 Albuquerque New Mexico 87102
Teva Investigational Site 13816 Amherst New York 14226
Teva Investigational Site 13817 New York New York 10019
Teva Investigational Site 13809 Raleigh North Carolina 27607
Teva Investigational Site 13839 Salisbury North Carolina 28144
Teva Investigational Site 13825 Cleveland Ohio 44195
Teva Investigational Site 13824 Philadelphia Pennsylvania 19107
Teva Investigational Site 13841 Richmond Texas 77307
Teva Investigational Site 13822 Virginia Beach Virginia 23454

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02964338, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 8, 2021 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02964338 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →